← Back to 6-APDB

6-APDB Stats & Data

Ema-3 4-desoxy-mda

PubChem CID 192599

NPS DataHub

MW177.25

FormulaC11H15NO

CAS152623-93-3

IUPAC1-(2,3-dihydro-1-benzofuran-6-yl)propan-2-amine

SMILESCC(N)Cc1ccc2CCOc2c1

InChIKeyVRNGXHJGMCJRSQ-UHFFFAOYSA-N

Phenethylamines Arylalkylamines

Chemical Class Substituted benzofuran

Psychoactive Class Psychedelic / Stimulant

Receptor Profile

Receptor Actions

Inhibitors

Serotonin-dopamine-norepinephrine reuptake inhibitor (SNDRI)

Other

Serotonin-dopamine-norepinephrine releasing agent (SNDRA)

Toxicity

PsychonautWiki

Due to only having a short history of human use, the toxicity and harm potential is not exactly known. Due to its similarity to MDMA, it is likely that the administration of repeated or high dosages of 6-APDB can be neurotoxic and cardiotoxic in some form. The exact toxic dosage is unknown. It is strongly recommended that one use harm reduction practices when using this drug.

Effect Profile

Curated + 1 Reports

Psychedelic 6.1

Strong visuals and auditory effects with mild body load, low headspace

Visual Intensity×3

Headspace Depth×3

Auditory Effects×1

Body Load / Somatic Effects×1

Empathogen 8.7

Strong euphoria, sensory enhancement, and empathy with moderate stimulation

Empathy / Social Openness×3

Euphoria / Mood Elevation×2

Stimulation×1

Sensory Enhancement×1

Stimulant 7.0

Strong euphoria with strong anxiety/jitters, moderate stimulation and focus

Stimulation / Energy×3

Euphoria / Mood Lift×2

Focus / Productivity×2

Anxiety / Jitters×1

Based on reports from:

Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 6-APDB

Tolerance & Pharmacokinetics

drugs.wiki

No tolerance chart. No study has measured how long tolerance to it lasts, so this page shows what is known instead of a curve.

No study has measured tolerance to 6-APDB in people. PsychonautWiki estimates that tolerance halves in 21-30 days and is gone in 2-3 months, without citing a source.

Sources: PsychonautWiki: 6-APDB

Experience Report Analysis

Erowid

2 Reports

1 Single-substance

2013–2014 Date Range

2 With Age Data

Demographics

Gender Distribution

Too few reports for a chart: gender is known from 2 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

Male 2 of 2

Age Distribution

Reports Over Time

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Canada	6-APDB is Schedule III in Canada as it is an analogue of MDA.	The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1.
France	6-APDB is classified as a narcotic since May 9, 2018, alongside other substances derived from benzofuran.
Germany	6-APDB is controlled under the NpSG ( New Psychoactive Substances Act ) as of November 26, 2016.	Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Italy	6-APDB is a prohibited substance in Italy.
Sweden	6-APDB is prohibited in Sweden as a "health hazard" as of 2009.
Switzerland	6-APDB is a controlled substance specifically named under Verzeichnis E.
United Kingdom	6-APDB is a class B drug in the United Kingdom since June 10, 2013.	It is banned by a blanket law on benzofurans and related compounds.
United States	6-APDB is unscheduled in the United States.	It may be considered an analog of MDA (which is a Schedule I drug under the Controlled Substances Act). As such, the sale and possession for the purposes of human consumption or could be prosecuted as crimes under the Federal Analog Act.

References

Data Sources

Cited References

← Back to 6-APDB